Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we discuss why comparing U.S. vaccine policy to Europe’s is a red herring, why the revolving door at the FDA between government and industry needs modernized rules, and more.
Terns drug shows strong early efficacy data
Terns Pharmaceuticals reported early but strong data on its next-generation CML drug, TERN-701, at the American Society for Hematology, STAT’s Adam Feuerstein writes. Major molecular response rates hit 64% at 24 weeks across four escalating doses — far above what Novartis’ Scemblix achieved in its Phase 1 study — in heavily pre-treated patients. Safety looked manageable, with no dose-limiting toxicities or pancreatitis and mostly expected cytopenias.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply